1.888.XLUMENA | contact us
Xlumena News
Press Release: Xlumena Receives CE Mark for NAVIX™, Second Product to Enter European Market
| On June 30, 2011 Xlumena announced that it received CE Mark approval for its NAVIX™ Access Device. The NAVIX™ is specifically designed and indicated for pancreatic pseudocyst access and tract dilation. |
Press Release: Xlumena Receives CE Mark for Revolutionary AXIOS™ Stent and Delivery System
| On May 5, 2011 Xlumena received CE Mark approval for the AXIOS™ Stent and Delivery System enabling it to begin a targeted commercial launch in select European markets. The AXIOS™ Stent is the only stent on the market in Europe specifically indicated for transmural pancreatic pseudocyst drainage. |
Press Release: Xlumena, Inc. Closes $7M Series B Venture Financing Round
| On April 28, 2011 Xlumena announced it had raised $7M led by a new investor, Aperture Venture Partners. Eric Sillman of Aperture Venture Partners and Avi Kometz, MD of Ascent Biomedical Ventures join Xlumena's Board of Directors. |
Press Release: FDA Clears Xlumena's NAVIX™ Access Device
| On April 8, 2010 Xlumena received FDA clearance for the NAVIX™ Access Device for pancreatic pseudocyst drainage. |
Recognized as an A-List Trend Setting Start Up
| Selected by START-UP magazine as one of the top 14 trend setting start-ups in 2008, Xlumena was identified as an innovative technology company with unique product opportunities and an A-List business model that will find investors regardless of the climate. |